Key Points
- Srinivas Akkaraju bought 96,000 shares of Alumis on December 2 at an average price of $7.55, a $724,800 transaction that raised his direct holdings to 912,849 shares (an 11.75% increase), valued at about $6.89 million.
- Across November 13–December 4, Akkaraju made multiple purchases totaling just over 1.07 million shares (about 1,078,876 shares) at prices ranging roughly from $5.25 to $8.18, signaling substantial insider accumulation.
Alumis Inc. (NASDAQ:ALMS - Get Free Report) Director Srinivas Akkaraju purchased 66,027 shares of the business's stock in a transaction that occurred on Thursday, December 4th. The stock was bought at an average price of $8.18 per share, for a total transaction of $540,100.86. Following the acquisition, the director owned 1,078,876 shares of the company's stock, valued at $8,825,205.68. This represents a 6.52% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.
Srinivas Akkaraju also recently made the following trade(s):
- On Wednesday, December 3rd, Srinivas Akkaraju bought 100,000 shares of Alumis stock. The shares were bought at an average cost of $7.75 per share, for a total transaction of $775,000.00.
- On Tuesday, December 2nd, Srinivas Akkaraju bought 96,000 shares of Alumis stock. The stock was purchased at an average price of $7.55 per share, with a total value of $724,800.00.
- On Monday, December 1st, Srinivas Akkaraju bought 86,350 shares of Alumis stock. The shares were acquired at an average price of $7.46 per share, for a total transaction of $644,171.00.
- On Friday, November 28th, Srinivas Akkaraju purchased 38,702 shares of Alumis stock. The stock was acquired at an average price of $7.64 per share, with a total value of $295,683.28.
- On Wednesday, November 26th, Srinivas Akkaraju purchased 48,537 shares of Alumis stock. The shares were acquired at an average cost of $7.64 per share, with a total value of $370,822.68.
- On Thursday, November 20th, Srinivas Akkaraju acquired 125,743 shares of Alumis stock. The stock was acquired at an average price of $7.20 per share, for a total transaction of $905,349.60.
- On Wednesday, November 19th, Srinivas Akkaraju bought 137,772 shares of Alumis stock. The shares were acquired at an average price of $6.56 per share, with a total value of $903,784.32.
- On Tuesday, November 18th, Srinivas Akkaraju purchased 102,652 shares of Alumis stock. The stock was bought at an average cost of $6.05 per share, for a total transaction of $621,044.60.
- On Monday, November 17th, Srinivas Akkaraju acquired 914 shares of Alumis stock. The shares were bought at an average price of $5.51 per share, with a total value of $5,036.14.
- On Thursday, November 13th, Srinivas Akkaraju bought 276,179 shares of Alumis stock. The stock was bought at an average cost of $5.25 per share, for a total transaction of $1,449,939.75.
Alumis Stock Up 11.7%
Shares of NASDAQ ALMS traded up $0.97 during trading on Friday, reaching $9.27. The company had a trading volume of 352,432 shares, compared to its average volume of 725,836. Alumis Inc. has a 12-month low of $2.76 and a 12-month high of $10.49. The business's 50-day moving average is $5.33 and its 200 day moving average is $4.44. The stock has a market cap of $967.80 million, a PE ratio of -2.31 and a beta of -1.87.
Alumis (NASDAQ:ALMS - Get Free Report) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.92) by ($0.14). The company had revenue of $2.07 million for the quarter, compared to the consensus estimate of $3.14 million. On average, analysts anticipate that Alumis Inc. will post -8.51 earnings per share for the current year.
Wall Street Analysts Forecast Growth
ALMS has been the subject of a number of research analyst reports. Morgan Stanley cut their target price on shares of Alumis from $23.00 to $22.00 and set an "overweight" rating for the company in a research report on Friday, August 15th. Wall Street Zen cut Alumis from a "hold" rating to a "sell" rating in a research report on Saturday, November 15th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Alumis in a research note on Tuesday, November 25th. Finally, HC Wainwright restated a "buy" rating and set a $14.00 target price on shares of Alumis in a research note on Thursday, August 14th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $19.20.
View Our Latest Stock Analysis on ALMS
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of ALMS. Russell Investments Group Ltd. grew its stake in shares of Alumis by 320.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,419 shares of the company's stock worth $26,000 after buying an additional 4,894 shares in the last quarter. Kera Capital Partners Inc. purchased a new position in Alumis in the second quarter worth about $32,000. Police & Firemen s Retirement System of New Jersey grew its position in Alumis by 199.7% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 10,753 shares of the company's stock worth $32,000 after acquiring an additional 7,165 shares in the last quarter. New York State Common Retirement Fund increased its stake in Alumis by 173.7% during the second quarter. New York State Common Retirement Fund now owns 11,767 shares of the company's stock worth $35,000 after acquiring an additional 7,467 shares during the last quarter. Finally, Western Wealth Management LLC purchased a new stake in Alumis during the second quarter valued at approximately $36,000.
Alumis Company Profile
(
Get Free Report)
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
